Skip to main content

Surrozen, Inc 8-K, filed Nov 9, 2026

Surrozen, Inc. (SRZN)

8-K 2026-11-09 For: 2026-11-09
View Original
Added on November 09, 2026

About this 8-K

Surrozen, Inc filed this 8-K on November 9, 2026.

Surrozen dosed the first patient in the DUET Phase 1b study and plans to expand Phase 2a enrollment from approximately 60 to 150 patients. Third-quarter net loss was $129.7 million, and anticipated cash runway extends into 2029. AI summary

Items reported

  • Item 2.02: Financial results
  • Item 9.01: Financial statements and exhibits